Nexlizet (bempedoic acid/ezetimibe) / Otsuka, Esperion Therap  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka
NCT03531905: Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C

Checkmark Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins.
Completed
2
242
US
Bempedoic acid + Ezetimibe FDC Oral Tablet, Ezetimibe 10 mg Oral Tablet, Zetia, Placebo Oral Tablet, Placebo oral capsule
Esperion Therapeutics
Diabetes, Diabetes Mellitus, Type 2, Cholesterolemia
06/19
06/19

Download Options